Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept versus placebo in high-risk WHO functional class III/IV pulmonary arterial hypertension
NL-OMON60566Phase 3Completed
- Sponsor
- Acceleron Pharma Inc.
- Start
- Jul 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Sotatercept plus background PAH therapy with Placebo plus background PAH therapy (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jul 2022; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON60566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60566.